atenolol has been researched along with Lassitude in 19 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 9.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 6.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Xamoterol was no different from placebo in these respects." | 6.67 | Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers. ( Faergeman, O; Jensen, HK; Sørensen, EV, 1991) |
| "When metoprolol responses were compared with those for atenolol, changes in exercise time and fatigue scores were significantly related to oxidation phenotype." | 6.67 | Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. ( Jackson, PR; Lennard, MS; Lewis, RV; Ramsay, LE; Tucker, GT; Yeo, WW, 1991) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 5.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 2.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Xamoterol was no different from placebo in these respects." | 2.67 | Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers. ( Faergeman, O; Jensen, HK; Sørensen, EV, 1991) |
| "When metoprolol responses were compared with those for atenolol, changes in exercise time and fatigue scores were significantly related to oxidation phenotype." | 2.67 | Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. ( Jackson, PR; Lennard, MS; Lewis, RV; Ramsay, LE; Tucker, GT; Yeo, WW, 1991) |
| " The metoprolol CR formulation displayed an even plasma concentration-time profile over the dosage interval while atenolol produced a peak at 2-4 h." | 2.67 | Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol. ( Dahlöf, CG; Dimenäs, ES; Heibel, B; Lücker, PW; Moore, RG; Olofsson, BK; Westergren, GE, 1990) |
| "Pharmacokinetic and pharmacodynamic properties of a new controlled-release (CR) formulation of metoprolol have been compared with those of atenolol." | 2.66 | Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol. ( Blomqvist, I; Jonsson, UE; Lundborg, P; Sandberg, A; Westergren, G, 1988) |
| "1%) were the most commonly reported clinical adverse experiences in patients treated with losartan." | 2.39 | Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 10 (52.63) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldberg, AI | 2 |
| Dunlay, MC | 2 |
| Sweet, CS | 2 |
| El-Haddad, B | 1 |
| Hammoud, D | 1 |
| Shaver, T | 1 |
| Shahouri, S | 1 |
| Komaroff, AL | 1 |
| Fellenius, E | 1 |
| Weiner, L | 1 |
| Rössner, S | 1 |
| Derman, WE | 1 |
| Dunbar, F | 1 |
| Haus, M | 1 |
| Lambert, M | 1 |
| Noakes, TD | 1 |
| Frishman, WH | 1 |
| Brobyn, R | 1 |
| Brown, RD | 1 |
| Johnson, BF | 1 |
| Reeves, RL | 1 |
| Wombolt, DG | 1 |
| Eagles, CJ | 1 |
| Kendall, MJ | 1 |
| Chelimsky, G | 1 |
| Chelimsky, T | 1 |
| Simpson, WT | 1 |
| Gullestad, L | 1 |
| Birkeland, K | 1 |
| Nordby, G | 1 |
| Larsen, S | 1 |
| Kjekshus, J | 1 |
| Sørensen, EV | 1 |
| Jensen, HK | 1 |
| Faergeman, O | 1 |
| Herbertsson, P | 1 |
| Fagher, B | 1 |
| Lewis, RV | 2 |
| Ramsay, LE | 2 |
| Jackson, PR | 2 |
| Yeo, WW | 1 |
| Lennard, MS | 1 |
| Tucker, GT | 1 |
| Dimenäs, ES | 1 |
| Dahlöf, CG | 1 |
| Heibel, B | 1 |
| Moore, RG | 1 |
| Olofsson, BK | 1 |
| Westergren, GE | 1 |
| Lücker, PW | 1 |
| Mroczek, WJ | 1 |
| Burris, JF | 1 |
| Hogan, LB | 1 |
| Citron, DC | 1 |
| Barker, AH | 1 |
| McDonald, RH | 1 |
| Blomqvist, I | 1 |
| Westergren, G | 1 |
| Sandberg, A | 1 |
| Jonsson, UE | 1 |
| Lundborg, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for atenolol and Lassitude
| Article | Year |
|---|---|
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 1995 |
Muscle fatigue and beta-blockers--a review.
Topics: Adaptation, Physiological; Adrenergic beta-Antagonists; Animals; Atenolol; Dogs; Dose-Response Relat | 1983 |
12 trials available for atenolol and Lassitude
| Article | Year |
|---|---|
Atenolol 50 mg or metoprolol 200 mg - a comparison of antihypertensive efficacy, side effects and lipoprotein changes.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Fatigue; Female; Heart Rate; Humans; Hype | 1983 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 1995 |
Amlodipine versus atenolol in essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Drug Administrat | 1994 |
The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects.
Topics: Adrenergic beta-Antagonists; Adult; Ammonia; Analysis of Variance; Anticholesteremic Agents; Atenolo | 1997 |
Nature and incidence of unwanted effects with atenolol.
Topics: Atenolol; Clinical Trials as Topic; Cold Temperature; Double-Blind Method; Extremities; Fatigue; Hum | 1977 |
Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; Blood Pressur | 1991 |
Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers.
Topics: Adrenergic beta-Agonists; Adult; Atenolol; Blood Pressure; Calcium; Exercise Test; Fatigue; Heart Ra | 1991 |
Effects of verapamil and atenolol on exercise tolerance in 5,000 m cross-country running: a double-blind cross-over study in normal humans.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Fatigue; Heart Rate; Humans; Male; Physical En | 1990 |
Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
Topics: Adult; Atenolol; Debrisoquin; Fatigue; Female; Humans; Male; Metoprolol; Oxidation-Reduction; Phenot | 1991 |
Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.
Topics: Aged; Atenolol; Delayed-Action Preparations; Double-Blind Method; Electrocardiography; Exercise Test | 1990 |
Comparison of the antihypertensive effects of betaxolol to atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Betaxolol; Blood Pressure; Bradycardia; Clinical Trials as To | 1988 |
Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.
Topics: Adult; Atenolol; Blood Pressure; Delayed-Action Preparations; Fatigue; Heart Rate; Humans; Male; Met | 1988 |
5 other studies available for atenolol and Lassitude
| Article | Year |
|---|---|
Malignancy-associated multicentric reticulohistiocytosis.
Topics: Antihypertensive Agents; Antineoplastic Agents; Arthralgia; Atenolol; Combined Modality Therapy; Dru | 2011 |
By the way, doctor. I am 81 with no history of heart problems. I recently developed atrial fibrillation and now take half of a 25-mg tablet of atenolol. The doctor says it's working, but it makes me extremely tired. Could you suggest another medication th
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Fatigue; Humans | 2006 |
Chronic beta-blockade does not influence muscle power output during high-intensity exercise of short-duration.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Benzopyrans; Blood Pressure; Cardiovascular Physiologi | 1993 |
Familial association of autonomic and gastrointestinal symptoms.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Autonomic Nervous System Diseases; Child; Fatigue; Fem | 2001 |
Side-effects of beta-blockers assessed using visual analogue scales.
Topics: Acebutolol; Adrenergic beta-Antagonists; Analysis of Variance; Atenolol; Dreams; Fatigue; Humans; Hy | 1985 |